Insight into the hypercoagulable state of high?risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies

Objective Most high-risk thrombotic antiphospholipid syndrome (APS) patients test positive for anti-?2-glycoprotein I (a?2GPI) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Information on the influence of these antibodies thrombin generation activated protein C resistance (aPCr) is still sparse contradictory. Methods Plasma 16 poured into a ?2GPI affinity column allowed perfect separation a?2GPI aPS/PT were further purified through prothrombin column. Obtained material was spiked normal pooled plasma (NPP) tested in assay absence or presence aPC. Results showed marked anticoagulant effect. Affinity from five compared. significantly prolonged lag time to peak (5.0 minutes [interquartile range (IQR)3.5–6.1] versus 2.7 [IQR2.2–3.5], P = .03 8.7 [IQR6.7–10.3] 5.7 [IQR4.5–6.2], .05, respectively) lower velocity index (143 nmol/L [IQR131–163] 171 [IQR157–182], 35 nmol/L/min [IQR32–59] 72 [IQR54–77], .03, respectively). When aPC added system, aPCr increased compared controls both However, it stronger using Median inhibition endogenous potential 22% (IQR16–33) with 52% (IQR46–56) (P .002). Conclusions A?2GPI show mild moderate procoagulant effect resistance. Conversely, strong aPCr.